Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Palliative Medicine
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Ellershaw, J. E
Right arrow Articles by Kelly, M. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ellershaw, J. E
Right arrow Articles by Kelly, M. J
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Corticosteroids and peptic ulceration

John E Ellershaw

St Christopher's Hospice, Sydenham, London

Moira J Kelly

St Christopher's Hospice, Sydenham, London

The relationship between corticosteroids and peptic ulceration, together with the major complications of gastrointestinal haemorrhage and perforation, remains an area of clinical concern. This paper reviews the literature regarding peptic ulceration and corticosteroids. Risk factors related to an increased incidence of peptic ulceration in patients prescribed corticosteroids are discussed. These include: total dose of corticosteroid, previous history of peptic ulceration, advanced malignant disease and concurrent prescribing of nonsteroidal anti-inflammatory drugs (NSAI Ds). It is suggested that prophylaxis should be considered for those patients with two or more risk factors. Choice and efficacy of prophylaxis is also considered.

Key Words: glucocorticosteroids • synthetic • palliative treatment • peptic ulcer

Palliative Medicine, Vol. 8, No. 4, 313-319 (1994)
DOI: 10.1177/026921639400800407
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Palliat MedHome page
A. Dickman and J. Ellershaw
For Discussion NSAIDs: gastroprotection or selective COX-2 inhibitor?
Palliative Medicine, June 1, 2004; 18(4): 275 - 286.
[Abstract] [PDF]

Home page
 StrokeHome page
B. J. Quilliam, K. L. Lapane, C. B. Eaton, and V. Mor
Effect of Antiplatelet and Anticoagulant Agents on Risk of Hospitalization for Bleeding Among a Population of Elderly Nursing Home Stroke Survivors
Stroke, October 1, 2001; 32(10): 2299 - 2304.
[Abstract] [Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
S. Jain, S. Datta, and D. Tundis
Management of Chronic Postthoracotomy Pain
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 1999; 3(3): 191 - 203.
[Abstract] [PDF]

Home page
 Journal Watch DermatologyHome page
Managing the Risks of Corticosteroid Therapy
Journal Watch Dermatology, May 1, 1998; 1998(501): 11 - 11.
[Full Text]